help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tonino, R. P.
Right arrow Articles by Ross, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tonino, R. P.
Right arrow Articles by Ross, P. D.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 9 3109-3115
Copyright © 2000 by The Endocrine Society

Original Studies

Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1

Richard P. Tonino, Pierre J. Meunier, Ronald Emkey, Jose A. Rodriguez-Portales, Charles-Joel Menkes, Richard D. Wasnich, Henry G. Bone, Arthur C. Santora, Mei Wu, Rena Desai, Philip D. Ross and for the Phase iii Osteoporosis Treatment Study Group

University of Vermont College of Medicine, Burlington, Vermont 05401

Address all correspondence and requests for reprints to: Dr. Richard P. Tonino, 1 South Prospect Street, Burlington, Vermont 05401. E-mail: richard.tonino{at}vtmednet.org

We report here the second 2-yr extension of a clinical trial among postmenopausal women; 235 women continued blinded treatment with 5 or 10 mg alendronate daily, and 115 women who had been treated with alendronate for 5 yr were switched to blinded placebo. Continuous treatment with alendronate (10 mg daily) for 7 yr increased lumbar spine bone mineral density (BMD) by 11.4% compared to baseline. After the initial 18 months, each additional year of treatment through yr 7 increased spine BMD by 0.8% for the 10-mg dose and 0.6% for the 5-mg dose, with significant increases during yr 6–7. Previously reported increases in BMD at other skeletal sites and decreases in biochemical markers of bone turnover remained stable during yr 6–7. Among women previously taking alendronate for 5 yr who were switched to placebo, there was no significant decline in BMD at the spine or hip, whereas small, but significant, decreases in BMD at the forearm and total body and small increases in biochemical markers were observed. The safety and tolerability profiles were similar to those of placebo. This is the largest published long-term study of antiresorptive therapy. Our findings indicate that long-term alendronate treatment is well tolerated and effective for 7 yr. Increases in spinal BMD continue for at least 7 yr, and other skeletal benefits are maintained. Discontinuation does not lead to accelerated bone loss, but continuous treatment yields better skeletal benefits than shorter treatment.




This article has been cited by other articles:


Home page
 JCOHome page
S. L. Greenspan, J. B. Nelson, D. L. Trump, J. M. Wagner, M. E. Miller, S. Perera, and N. M. Resnick
Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy
J. Clin. Oncol., September 20, 2008; 26(27): 4426 - 4434.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. Stroup, M. P. Kane, and A. M. Abu-Baker
Teriparatide in the treatment of osteoporosis
Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
M. Ramachandran, K. Ward, R. R. Brown, C. F. Munns, C. T. Cowell, and D. G. Little
Intravenous Bisphosphonate Therapy for Traumatic Osteonecrosis of the Femoral Head in Adolescents
J. Bone Joint Surg. Am., August 1, 2007; 89(8): 1727 - 1734.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
H. Liu, K. Michaud, S. Nayak, D. B. Karpf, D. K. Owens, and A. M. Garber
The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis.
Arch Intern Med, June 12, 2006; 166(11): 1209 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
A. S. Shanbhag
Use of bisphosphonates to improve the durability of total joint replacements.
J. Am. Acad. Ortho. Surg., April 1, 2006; 14(4): 215 - 225.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. V. Odvina, J. E. Zerwekh, D. S. Rao, N. Maalouf, F. A. Gottschalk, and C. Y. C. Pak
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1294 - 1301.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. R. McClung, R. D. Wasnich, D. J. Hosking, C. Christiansen, P. Ravn, M. Wu, A. M. Mantz, J. Yates, P. D. Ross, A. C. Santora II, et al.
Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4879 - 4885.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
B J Smith, L L Laslett, K D Pile, P J Phillips, G Phillipov, S M Evans, A J Esterman, and J G Berry
Randomized controlled trial of alendronate in airways disease and low bone mineral density
Chronic Respiratory Disease, July 1, 2004; 1(3): 131 - 137.
[Abstract] [PDF]

Home page
 NEJMHome page
H. G. Bone, D. Hosking, J.-P. Devogelaer, J. R. Tucci, R. D. Emkey, R. P. Tonino, J. A. Rodriguez-Portales, R. W. Downs, J. Gupta, A. C. Santora, et al.
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
N. Engl. J. Med., March 18, 2004; 350(12): 1189 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Podiatr. Med. Assoc.Home page
K. A. McGarry and M. G. Cyr
Principles of Diagnosing and Managing Postmenopausal Osteoporosis for the Podiatric Physician
J Am Podiatr Med Assoc, March 1, 2004; 94(2): 187 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki
Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. P. Ettinger
Aging Bone and Osteoporosis: Strategies for Preventing Fractures in the Elderly
Arch Intern Med, October 13, 2003; 163(18): 2237 - 2246.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
G. A. Rodan and A. A. Reszka
Osteoporosis and Bisphosphonates
J. Bone Joint Surg. Am., August 1, 2003; 85(90003): 8 - 12.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. L. Ma, H. U. Bryant, Q. Zeng, A. Schmidt, J. Hoover, H. W. Cole, W. Yao, W. S. S. Jee, and M. Sato
New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats
Endocrinology, May 1, 2003; 144(5): 2008 - 2015.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. F Eichner, K. B Lloyd, and E. M Timpe
Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment
Ann. Pharmacother., May 1, 2003; 37(5): 711 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
B. H. Ascott-Evans, N. Guanabens, S. Kivinen, B. G. A. Stuckey, C. H. Magaril, K. Vandormael, B. Stych, and M. E. Melton
Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy: A Randomized Controlled Trial
Arch Intern Med, April 14, 2003; 163(7): 789 - 794.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Simha, J. E. Zerwekh, K. Sakhaee, and A. Garg
Effect of Subcutaneous Leptin Replacement Therapy on Bone Metabolism in Patients with Generalized Lipodystrophy
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4942 - 4945.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. R. Jenny-Avital, V. Treloar, I. R. Reid, P. Burckhardt, and J. P. Brown
Bisphosphonates and Osteoporosis
N. Engl. J. Med., June 27, 2002; 346(26): 2088 - 2089.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., A. Colao, C. di Carlo, T. Sena, G. Lombardi, F. Zullo, and P. Mastrantonio
Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1502 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Hochberg, S. Greenspan, R. D. Wasnich, P. Miller, D. E. Thompson, and P. D. Ross
Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1586 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. Wartofsky
Update in Endocrinology
Ann Intern Med, October 16, 2001; 135(8_Part_1): 601 - 609.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. M. Ott
Fractures after Long-Term Alendronate Therapy
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1835 - 1835.
[Full Text]

Home page
 JWatch GeneralHome page
Long-term Follow-up Now Available for Alendronate
Journal Watch (General), October 20, 2000; 2000(1020): 3 - 3.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society